| Background and Objective:Multiple myeloma is a malignant neoplasm of the blood system in the middle and elderly patients,the incidence rate is increasing yearly,and now it is still an incurable disease,So it is necessary to explore effective treatments.Early-stage studies have confirmed that aspirin can resist myeloma cells by a variety of mechanisms.This research intends to evaluate the clinical efficacy of aspirin in the treatment of multiple myeloma patients by reviewing the clinical data of 92 patients with multiple myeloma,so that to provide clinical basis for the anti-tumor effect of aspirin.Methods:Collecting the primary treatment of 92 patients with multiple myeloma in our hospital,all patients were treated with boron-based bortezomib chemotherapy regimen or VAD-T regimen for 2-6 treatments.All patients are classified as ASA treatment Group and non-ASA treatment group according to whether or not used aspirin.Correlation analysis uses Spearman test.Using SPSS19.0 software to analyse the efficacy and incidence of adverse reactions in the two treatment groups,p <0.05 is considered statistically significant for the difference.Results:1.The total effective rate of ASA treatment group and non-ASA treatment group was 90.9% and 64.4%,the difference was statistically significant(P=0.005).In the patients who were treated with bortezomib-based chemotherapy regimens,the effective rate of ASA treatment group and non-ASA treatment group was 95.7% and 70.3%,the difference was statistically significant(P = 0.017).In the patients who used VAD-T chemotherapy regimen,the effective rate of ASA treatment group and non-ASA treatment group was 80% and 54.5%,and the difference was no statistically significant(P>0.05).In light-chain and non-light-chain patients,the effective rate of ASA treatment group was higher than non-ASA treatment group(P <0.05).In the stage of ISSI and Ⅱ Patients,the effective rate of ASA treatment group and non-ASA treatment group was 94.7% and 67.7%,the difference was statistically significant(P = 0.025).In ISS Ⅲ patients,the effectiveness of ASA treatment Group and non-ASA treatment group was 85.7% and 60.7% respectively,the difference was no statistically significant(P > 0.05).In patients with normal renal function,the effective rate of ASA treatment Group and non-ASA treatment group was 96.3% and 68.1% respectively,and the difference was statistically significant(P=0.005).In patients with renal insufficiency,the effectiveness of ASA treatment Group and nonASA treatment group was 66.7% and 50% respectively,and there was no statistically significant(P > 0.05).2.The incidence of adverse reactions in the two treatment groups was as follows: The incidence of deep vein thrombosis in the ASA group was lower than that in the non-ASA group(P <0.05).And there was no significant difference in the incidence of other adverse reactions.Conclusions:1.The overall efficacy of the ASA-treated group was higher than that in the nonASA treatment group;The patients with normal renal function or in stage of ISS I 、Ⅱ phase,the efficacy of ASA treatment group was better than that of non-ASA treatment group,as same as the the light or non-light chain patients.2.Aspirin combined with bortezomib-based chemotherapy regimen can significantly improve the treatment efficiency.3.Aspirin can reduce the incidence of deep venous thrombosis,and does not increase the risk of other adverse reactions. |
